XTRA:T5O

Stock Analysis Report

Executive Summary

CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies.


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has CytoTools's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: T5O has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

7.5%

T5O

-8.1%

DE Biotechs

0.06%

DE Market


1 Year Return

56.0%

T5O

5.9%

DE Biotechs

14.8%

DE Market

Return vs Industry: T5O exceeded the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: T5O exceeded the German Market which returned 17.1% over the past year.


Shareholder returns

T5OIndustryMarket
7 Day7.5%-8.1%0.06%
30 Day14.7%-1.8%1.8%
90 Day12.3%11.4%7.1%
1 Year56.0%56.0%6.1%5.9%18.4%14.8%
3 Year-0.7%-0.7%56.9%55.2%17.4%7.0%
5 Year-81.0%-81.0%16.4%13.9%27.9%10.4%

Price Volatility Vs. Market

How volatile is CytoTools's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CytoTools undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: T5O (€11.5) is trading below our estimate of fair value (€137.71)

Significantly Below Fair Value: T5O is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: Insufficient data to calculate T5O's PE Ratio to determine if it is good value compared to the Biotechs industry average.

PE vs Market: Insufficient data to calculate T5O's PE Ratio to determine if it is good value compared to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate T5O's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: Insufficient data to calculate T5O's PB Ratio to determine if it is good value.


Next Steps

Future Growth

How is CytoTools forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

38.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CytoTools has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has CytoTools performed over the past 5 years?

22.4%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if T5O has high quality earnings.

Growing Profit Margin: Insufficient data to determine if T5O's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if T5O's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare T5O's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if T5O's earnings growth over the past year exceeded the Biotechs industry average.


Return on Equity

High ROE: T5O has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is CytoTools's financial position?


In this section we usually analyse CytoTools's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. CytoTools has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of T5O’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. CytoTools's cash and debt levels may be found in its annual reports archived here.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when CytoTools's financial data was last updated here.
  • Explore more healthy companies in the Pharmaceuticals & Biotech industry.

Dividend

What is CytoTools's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.5%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate T5O's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate T5O's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if T5O's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if T5O's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of T5O's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of CytoTools's salary, the management and board of directors tenure and is there insider trading?


CEO

Mark-André Freyberg 0

20yrs

Tenure

0

Dr. Mark-André Freyberg co-founded CytoTools AG in 2000 and serves as Chief Executive Officer and Chairman of Management Board also served as its Managing Director. Dr. Freyberg served as the Head of Proje ...


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Management Team

  • Mark-André Freyberg

    Chairman of Management Board & CEO

    • Tenure: 20yrs
  • Peter Friedl

    Vice-Chairman of Management Board & Member of Supervisory Board

    • Dirk Kaiser

      Co-Founder


      Board Members

      • Peter Friedl

        Vice-Chairman of Management Board & Member of Supervisory Board

        • Heiner Hoppmann (61yo)

          Member of Supervisory Board

          • Tenure: 2.4yrs
        • Manfred May

          Chairman of Supervisory Board

          • Herr Hoffmann

            Member of Supervisory Board

            • Bernhard Seehaus

              Member of Supervisory Board

              • Ruediger Weseloh

                Member of Supervisory Board

                Company Information

                CytoTools AG's company bio, employee growth, exchange listings and data sources


                Key Information

                • Name: CytoTools AG
                • Ticker: T5O
                • Exchange: XTRA
                • Founded: 2000
                • Industry: Biotechnology
                • Sector: Pharmaceuticals & Biotech
                • Market Cap: €30.801m
                • Shares outstanding: 2.69m
                • Website: https://cytotools.de

                Number of Employees


                Location

                • CytoTools AG
                • Klappacher Strasse 126
                • Darmstadt
                • Hessen
                • 64285
                • Germany

                Listings

                TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
                T5ODB (Deutsche Boerse AG)YesBearer SharesDEEURDec 2006
                T5OXTRA (XETRA Trading Platform)YesBearer SharesDEEURDec 2006
                T5ODBATS-CHIXE (BATS 'Chi-X Europe')YesBearer SharesGBEURDec 2006

                Biography

                CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company’s therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany. 


                Company Analysis and Financial Data Status

                All financial data provided by Standard & Poor's Capital IQ.
                DataLast Updated (UTC time)
                Company Analysis2020/01/18 21:03
                End of Day Share Price2020/01/17 00:00
                Earnings2018/06/30
                Annual Earnings2017/12/31


                Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.